Overview

Developing Potential High-impact Therapies in Autoimmune Diseases and Cancer

At Cullinan Therapeutics, our mission is to develop potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. We identify high-impact targets, which we define as those that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer, and then select what we believe is the optimal therapeutic modality for those targets. Using this strategy, we have built a pipeline of targeted immunology and oncology product candidates that aim to maximize therapeutic potential for patients.

Learn more View our R&D pipeline

Minimum 15 minutes delayed. Source: LSEG

Events

2026 Leerink Global Healthcare Conference
March 10, 2026 4:20 PM EDT
TD Cowen 46th Annual Healthcare Conference
March 3, 2026 1:10 PM EST
Citi 2026 Virtual Oncology Leadership Summit
February 19, 2026 10:00 AM EST
View all events

Presentations